AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05109845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spheres & Shield Maze Task
Description: A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards.
Study NCT06319261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided biofilm therapy
Description: Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.
Study NCT06319261 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: root surface debridement
Description: Removing plaque and calculus by conventional root surface debridement
Study NCT06628479 — intervention group
Intervention type: OTHER
Intervention: interleukin, enzyme, hormone
Description: Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
Study NCT06628674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core muscle exercise
Description: Patients in experiment group will do core muscle exercise with online interactive videos
Study NCT06628674 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pelvic muscle exercise
Description: Patients in experiment group will do pelvic muscle exercise without online interactive videos
Study NCT06631547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Hormonal treatment
Study NCT06631547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The usual head trauma care
Description: the basic treatment
Study NCT06631547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The usual head trauma care
Description: the basic treatment
Study NCT04889066 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy
Description: 24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm.
Study NCT04889066 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiation Therapy
Description: 24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm.
Study NCT04889066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study NCT06628466 — intervention group
Intervention type: DRUG
Intervention: Nuberol Forte
Description: Quality of Life study
Study NCT06630182 — intervention group
Intervention type: OTHER
Intervention: Bortner self-questionnaire
Description: 14 items
Study NCT06630182 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire BFI-10
Description: 10 items
Study NCT06631131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization with clear aligners supported by Class II elastics
Description: Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.
Study NCT06631131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization with clear aligners supported by miniscrew
Description: Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
Study NCT06631118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B
Description: Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
Study NCT06629883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REPS w/BANDS
Description: This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
Study NCT06700993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual in Collaborative Care or Integrated Behavioral Health
Description: Treatment as Usual will be whatever primary care and behavioral health services are standardly implemented for adolescents or young adults experiencing suicidality
Study NCT06700993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connections model
Description: The Connections model applies the Aeschi Model of suicide care to Collaborative Care or other Integrated Behavioral Health by centering the patient's clinical narrative, focusing treatment on the patient's unique drivers of suicide, and maximizing collaboration while maintaining the standards of suicide assessment and management expected by accrediting bodies.
Study NCT06705413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.
Study NCT06705413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.
Study NCT06705413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiome diet
Description: The participants will receive Microbiome diet for three consecutive menstrual cycles. A three-phase diet (21-day phase, 28-day phase and maintenance phase) will be followed by the experimental group which contains some food restrictions and addition for certain food types which may improve gut health.
Study NCT06704945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary surgery
Description: BCS only. Ommission of axillary surgery. No axillary surgery after neoadjuvant chemotherapy.
Study NCT06704945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary surgery
Description: BCS with SLNB(+/-ALND)
Study NCT04889066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study NCT06711497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global postural reeducation exercises
Description: Subjects will be trained on global postural reeducation exercises (GPR) and active neck exercises. At each session, they will maintain two different lying postures to stretch anterior and posterior muscle chain and one standing posture to integrate the postural correction into activity of daily living (ADL.Initially, without gravity load, a lying posture was applied to the anterior muscle chain for approximately 15 min, then another lying posture to the posterior muscle chain for other 15 min, and finally the patients worked in a standing posture for postural integration under a gravity load for 5 min.
Study NCT06711497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep neck flexor activation exercise
Description: Subjects will be trained on deep neck flexor activation using pressure biofeedback and active neck exercises . The pressure sensor will be put under the neck and will be asked to de gentle nod as if saying yes so that the pressure sensor measures 2mmHg above baseline (20mmHg), then 4mmHg, followed by 6mmHg,8mmHg, and 10 mmHg without rests in between. the pressure sensor should read 30mmHg at the end of the movement sequence. Patient will hold each increment for 2 seconds, 10 seconds total after all 5 increments. Highest level achieved will be repeated with the correct form until a total of 10 reps with 10-second holds will be achieved in three series with 30 seconds of interval between the series plus active neck flexor exercise
Study NCT06712654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 75mg TID
Description: receiving orally AP306 75mg (one tablet), three times a day
Study NCT06712654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 100mg TID
Description: receiving orally AP306 100 mg (one tablet), three times a day.
Study NCT06712654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 125mg TID
Description: receiving orally AP306 125 mg (one tablet), three times a day
Study NCT06712654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 125mg BID
Description: receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet
Study NCT06712654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP306 150mg BID
Description: receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet
Study NCT06712654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TID
Description: receiving orally one placebo tablet of AP306, three times a day
Study NCT06712667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee with different amounts of caffeine.
Study NCT06712667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee with different amounts of caffeine.
Study NCT06711120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively
Description: During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.
Study NCT06711848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A web-based educational intervention on oral cancer
Description: This intervention will involve administering education, via a website, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
Study NCT06121947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The DBS electrodes are implanted into MLR.
Description: MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
Study NCT06121947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The electrodes are implanted into the patient's vagus nerve
Description: A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
Study NCT06711848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A mobile health app-based educational intervention on oral cancer
Description: This intervention will involve administering education, via a mhealth application prototype, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (B)
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT327
Description: Intravenous infusion
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Intravenous infusion
Study NCT05257577 — intervention group
Intervention type: PROCEDURE
Intervention: Breast conserving surgery
Description: Patients receive standard of care breast surgery and subsequent whole breast irradiation
Study NCT06112340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linsitinib
Description: Study medication taken twice daily by mouth
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Velo-NP
Description: Velo-NP; 10 mg nicotine;
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid (D)
Description: Oral daily dosage of 300mg.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid (Pa)
Description: Oral daily dosage of 200mg.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)
Description: Oral daily dosage of 400mg.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid (L)
Description: Oral daily dosage of 600mg for the first 8 weeks.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide (Z)
Description: Oral daily dosage of 1200mg-2000mg depending on weight.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Description: Oral daily dosage of 1200mg-2000mg depending on weight.
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zyn-NP
Description: Zyn-NP; 3 mg nicotine;
Study NCT05940233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
Study NCT05940233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin (R)
Description: Oral daily dosage of 450mg-750mg depending on weight.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (H)
Description: Oral daily dosage of 225mg-375mg depending on weight.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol (E)
Description: Oral daily dosage of 825mg-1375mg depending on weight.
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous infusion
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Intravenous infusion
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous infusion
Study NCT06227351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: completely limiting computer generated surgical three-dimensional guide
Description: Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed.
Study NCT06227351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partially limiting computer generated surgical three-dimensional guide
Description: Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed.
Study NCT05903339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 Pr-NP1 60mcg
Description: (60 mcg)
Study NCT06712316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous infusion
Study NCT06707818 — intervention group
Intervention type: OTHER
Intervention: Preoperative Interventions
Description: During the initial surgical consultation, participants will provide informed consent. Demographic data and several validated assessment scales will be collected, including the Perceived Socioeconomic Status Scale (8), Ten-Item Personality Inventory (9), Pain Catastrophizing Scale (10), Hospital Anxiety and Depression Scale (11), Rosenberg Self-Esteem Scale (12), Quality of Recovery-15 (QoR-15) questionnaire (13), and the Visual Analog Scale (VAS) for pain (14).
Study NCT05249699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: prevent the development of tuberculosis
Study NCT05249699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: without any additional anti-tuberculosis treatment
Description: reduce the number of Participants With Treatment-Related Adverse Events
Study NCT05759611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
Description: Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session